Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

Inclusion Criteria: * Previously diagnosed Atopic Dermatitis with active, visible flare-ups at time of screening * Present dry/itchy skin patches on forearm, back of the hand, or posterior lower leg suitable for treatment assessment * Evidence of inflammatory disease (documented diagnosis and current active symptoms) * Stable skincare routine for 4 weeks prior to screening * Subject willing to avoid conflicting topical treatments during study period * Subject being used to applying topical treatments for atopic dermatitis General: * Healthy subject apart from atopic dermatitis * Subject having given free informed, written consent * Subject willing to adhere to protocol and study procedures Exclusion Criteria: * Pregnant or nursing woman or woman planning to get pregnant during the study * Recent (within 4 weeks) or current history of using atopic dermatitis biological drugs, such as dupilumab, lebrikizumab, nemolizumab, and tralokinumab * Recent use of systemic antibiotics, steroids, or immunomodulators (within 4 weeks) * Active skin infections unrelated to atopic dermatitis * Severe dermatologic conditions requiring immediate medical intervention * Use of topical or systemic treatment during previous weeks liable to interfere with assessment * Subject having undergone surgery under general anaesthesia within the previous month * Excessive exposure to sunlight or UV-rays within the previous month * Subject having scars, tattoos on the forearms that would interfere with assessments * Subject enrolled in another clinical trial during the study period and/or during the past 30 days